ARID4B and prostate carcinoma: Consistent with these results, knockdown of ARID4B in the DU145 and LNCaP human prostate cancer cell lines reduced expression or phosphorylation of the core regulators and downstream effectors of the PI3K-AKT pathway (Supplementary Fig. 3).